Oncology

Latest News

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

By Cameron Santoro

August 21st 2025

RIsing costs for therapies and inequities in reimbursement for genomic testing have created financial barriers for patients, according to appearing experts in Detroit, Michigan, on July 10, 2025.

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 24th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 24th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Segment 8 - Treatment's Financial Constraints

January 2nd 2014

Segment 8 - Treatment's Financial Constraints

The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.

Segment 7 - Cost Considerations

January 2nd 2014

Segment 7 - Cost Considerations

Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.

Segment 5 - Value-based Decisions in NSCLC

January 2nd 2014

Segment 5 - Value-based Decisions in NSCLC

Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.

December 31st 2013

Healthcare Headlines in 2013

A look back at some of the InFocus blog highlights of 2013.

Segment 4 - Screening

December 30th 2013

Segment 4 - Screening

Panelists discuss screening recommendations and guidelines, including considerations for screening those patients with a smoking history.

Segment 3 - Treatment Considerations

December 30th 2013

Segment 3 - Treatment Considerations

The panelists weigh in on the appropriate standards for treating patients with NSCLC.

Segment 2 - Histology, Targeted Therapy and Surgery

December 30th 2013

Segment 2 - Histology, Targeted Therapy and Surgery

Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

Segment 1 - Introduction to NSCLC

December 30th 2013

Segment 1 - Introduction to NSCLC

Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).

December 30th 2013

For Cancer Survivors, 2014 Will Be the Year to Plan

The coming year will be one for those who have beaten cancer to develop survivorship plans, with the Commission on Cancer to require planning by treatment centers starting in 2015.

December 28th 2013

Discussion 8: Redefining the Role of Industry in Contemporary Healthcare

Cliff Goodman, PhD John L. Fox, MD, MHA Bo Gamble

The final panel of the conference analyzes the role of the industry in healthcare, including panelists' observations on topics such as innovation. Mr Gamble, for instance, offers his insights as to how groups like the Community Oncology Alliance are working with the industry to drive the message about the quality and the value component throughout all the stakeholders. Dr Fox provides perspective on how payers can offer valuable partnerships throughout the industry, including those with pharmaceutical companies.

December 28th 2013

Discussion 7: Value-Based Pricing: The Role of Outcomes Data in Pricing Models

Cliff Goodman, PhD Jeffrey D. Dunn, PharmD, MBA Michael E. Chernew, PhD Kirby Eng, RPh

Dr Cliff Goodman leads a discussion featuring panelists including The American Journal of Managed Care's co-editor-in-chief, Dr Michael Chernew. Topics of the discussion include the impact of value-based pricing in the market, and how different pricing models such as bundled payments or accountable care organizations impact risk factors.

December 28th 2013

Presentation 7: Where Does HEOR Fit in the Oncology Model?

Scott D. Ramsey, MD, PhD

According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.

December 28th 2013

Discussion 6: Nextâ€Generation Genetic Sequencing in Oncology: Ready for Prime Time?

Ira M. Klein, MD, MBA, FACP Michael Kolodjiez, MD Lee N. Newcomer, MD, MHA John L. Fox, MD, MHA Jerry Conway

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

December 28th 2013

Presentation 6: The Present (and Future) of Genetic Profiling in Oncology

Jerry Conway provides a DNA-centric view of organizing treatment plans with respect to the use of some advances in genomic technology.

December 28th 2013

Discussion 5: Companion Diagnostics in Targeted Treatments

Ira M. Klein, MD, MBA, FACP Jan Berger, MD, MJ Mike Kolodziej, MD

Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.

December 28th 2013

Presentation 5: Payer Perspectives on Genetic Counseling

Karen Lewis, MS, MM, CGC

Karen uses this session to analyze payer perspectives in genetic counseling. She describes the process involved with genetic counseling and the role of the counselor. She notes that the path to becoming a genetic counselor can often be more rigorous than in other specialties. Ms Lewis also discusses the surge of interest that genetic counseling has seen in recent years.

December 28th 2013

Presentation 4: An Update on Clinical Pathways

Bruce A. Feinberg, DO

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.

December 28th 2013

Discussion 3: Challenges and Opportunities for Quality Measures in Oncology

Ira M. Klein, MD, MBA, FACP Lee N. Newcomer, MD, MHA Phyllis Torda Dennis Scanlon, PhD

Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are not enough PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the nimbleness of structuring data.

December 28th 2013

Presentation 3: Defining and Measuring Quality Outcomes in Oncology

Lee N. Newcomer, MD, MHA

Dr Newcomer says that he welcomes the transition of oncology from being evaluated in process measures to outcome measures. He says that while quality measures can be quick and messy, these results are used for the purpose of finding gaps and seeing if those gaps can be improved.

December 28th 2013

Discussion 2: Implications of Healthcare Reform: 'Noâ€ Will Be Heard

Cliff Goodman, PhD A. Mark Fendrick, MD John L. Fox, MD, MHA Ira M. Klein, MD, MBA, FACP

Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.

December 28th 2013

Presentation 2: Incorporating Patient-Centered Outcomes in Clinical Trials

Ethan Basch, MD

Ethan Basch, MD, a self-described triple-threat, discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague's published research article, Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.

December 28th 2013

Presentation 1: Oncology Practice in the Era of PCMHs and ACOs: Square Pegs or Round Holes?

Peter B. Bach, MD, MAPP

Dr Peter Bach says professionals are looking at opportunities for new payment models and care redesign, but there are also threats that might surface. Each type of insurance payment model has different levels of risk factors. New payment models, such as the UHC pathways program and CMMI demo, have limited risk.

December 26th 2013

Value of Genetic Testing in Breast Cancer

The value of genetic testing in breast cancer is subject to debate, but it also holds promise. One recent clinical trial simulated by a group of researchers, for instance, found that the 7 single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was cost-effective when used for MRI screenings in patients at intermediate risk of developing the disease over their lifetime.

December 23rd 2013

Economics of Genomic Testing for Women With Breast Cancer

Robert D. Lieberthal, PhD

All the economic studies of genomic tests for breast cancer rely on modeling rather than randomized controlled trials or other direct trial data.

December 20th 2013

Outrage at the Increasingly High Cost of Cancer Drugs

Cancer drug prices have doubled in the past decade, from an average of $5,000 per month to more than $10,000.

December 13th 2013

The Quest for Better Survivorship: Guidelines Promote More Accountable Cancer Care

December 13th 2013

FDA Approves Ibrutinib for Mantle Cell Lymphoma

December 13th 2013

Genetic Testing Should Come With Counseling: American Cancer Society CMO, Supreme Court Plaintiff Among Experts Who Warn of Consumer Risks

December 13th 2013

Oncology Groups Active in Effort to Repeal SGR

Mary K. Caffrey

December 13th 2013

Current Thinking Behind Decision Making in Oncology Clinical Pathway Design

Rhonda Greenapple, MSPH

...

169 170 171 172 173 174 175 176 177

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions